NASDAQ:GALT
Galectin Therapeutics Inc.
Galectin Therapeutics Inc. reported net income of −$30.8M in fiscal 2025. The diluted share count rose 2.6%.Summary generated from Galectin Therapeutics Inc.'s SEC filings. Latest annual report filed Mar 31, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+2.6%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −30 | −38 | −38 | −42 | −20 |
| Net income | −31 | −39 | −41 | −47 | −31 |
| Free cash flow | n/a | n/a | n/a | n/a | n/a |
Recent filings
- 8-KResults of operations and financial condition
Aug 14, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 14, 2026 - 4Insider transaction report
Aug 4, 2026 - 8-KCurrent report
Aug 4, 2026 - 4Insider transaction report
Jul 16, 2026 - 8-KRegulation FD disclosure
Jun 23, 2026 - 8-KResults of operations and financial condition
May 15, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 15, 2026